ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Novel fenoterol derivatives as suppressors of ERK1/2 phosphorylation in melanoma.
Jakub Wójcik, Sylwia Wnorowska, Weronika Miziewicz, Giulia Tassinari, Gabriela Misiurek, Robert Kostecki, Agata Małek, Anna Boguszewska-Czubara, Irving W Wainer, Artur Wnorowski
Abstract read
In one paragraphArticle in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Jakub WójcikDepartment of Biopharmacy, Medical University of Lublin, Lublin, Poland.
Sylwia WnorowskaDepartment of Medical Chemistry, Medical University of Lublin, Lublin, Poland.
Weronika MiziewiczDepartment of Biopharmacy, Medical University of Lublin, Lublin, Poland.
Giulia TassinariDepartment of Biopharmacy, Medical University of Lublin, Lublin, Poland.
Gabriela MisiurekDepartment of Biopharmacy, Medical University of Lublin, Lublin, Poland.
Robert KosteckiDepartment of Biopharmacy, Medical University of Lublin, Lublin, Poland.
Agata MałekDoctoral Schoolof the Medical University of Lublin, Lublin, Poland.
Anna Boguszewska-CzubaraDepartment of Medical Chemistry, Medical University of Lublin, Lublin, Poland.
Irving W WainerLaboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
Artur WnorowskiDepartment of Biopharmacy, Medical University of Lublin, Lublin, Poland. artur.wnorowski@umlub.edu.pl.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Melanoma is a highly aggressive cancer with limited therapeutic options. In melanoma cell lines, β
Indexed as
Adrenergic beta-2 Receptor AgonistsAntineoplastic AgentsFenoterolMelanomaMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3AnimalsCell Line, TumorCell ProliferationHumansPhosphorylationReceptors, Adrenergic, beta-2StereoisomerismStructure-Activity RelationshipXenograft Model Antitumor AssaysZebrafishAdrenergic beta-2 Receptor AgonistsAntineoplastic AgentsFenoterolMAPK1 protein, humanMAPK3 protein, humanMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Receptors, Adrenergic, beta-2Beta adrenergic receptor signalingExchange protein directly activated by cAMPNaphthylfenoterol derivativesPharmacological modulation of ERK signalingRaf/MEK/ERK pathwayStereochemistry
Identifiers
PMID42322356
PMCPMC13593774
What OpenQuestion holds
Textmetadata
Read underepoch 390